Abstract
IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have